|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Long gone are the days when Africa was disparagingly regarded as the White Man’s Burden.
Yahoo Finance's Seana Smith, Myles Udland and Dan Roberts, along with Morning Breath co-hosts Claudia Oshry and Jackie Oshry, offer their suggestions on who United, Facebook, Uber and Chipotle should pick as their next brand rep.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss a Bloomberg report that the Securities and Exchange Commission and Commodity Futures Trading Commission are investigating manipulation in volatility-related securities.
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action as Warren Buffett prepares to send his annual letter to Berkshire Hathaway investors and disclose how much his stash of cash has grown—as well as what, if any, plans he has for it.
Roku shares were deep in the red on Thursday after a big earnings disappointment. Let's take a look at both the long and the short case, as we get technical with Jared Blikre.
Although Twitter (TWTR) returned to revenue growth in 4Q17 and delivered its first-ever GAAP (generally accepted accounting principles) profit as a public company, not everyone on Wall Street celebrated these results. As soon as Twitter’s 4Q17 results came out, showing that revenues had grown 2.0% YoY (year-over-year) and surpassed the consensus estimate by about $46 million, Pivotal Research sent out a research note to clients telling them they shouldn’t be too excited. According to the note, which was cited by CNBC, Pivotal downgraded Twitter’s stock to “sell” from “hold,” warning that the company could have a difficult time competing with Facebook (FB) and Alphabet’s (GOOGL) Google for digital advertising dollars.
The fallout over this week's shooting rampage at a Florida high school started to take its toll on National Rifle Association's roster of corporate partners on Friday as a half dozen companies severed marketing ties with the gun advocacy organzation. The exodus of corporate names, ranging from a major insurer to car rental brands and a household moving company, occurred after the NRA launched a counter-offensive against a student-led campaign for tighter U.S. gun ownership laws. At the same time, gun control activists are stepping up pressure on Amazon.com Inc and other online streaming platforms to drop the online video channel NRATV, featuring gun-friendly programming produced by the NRA.
General Electric Co (NYSE:GE) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Say what you will about Apple Watch—and pundits have said plenty—but it is considered a major force behind an estimated $29 billion wearables market by 2022. Market researcher CCS Insight predicts 71 million smartwatches will be sold this year, doubling to 140 million by 2022—helping to fuel $29 billion in wearable sales by 2022. Apple Watches are leading the way, with shipments of 16 million units this year, up 60% from 2017.
General Electric Co added 18,000 thousand employees to its worldwide workforce last year, a 6.1 percent increase that comes as the company is trying to cut costs to shore up its profits, according to a ...
NEW YORK (Reuters) - General Electric Co (GE.N) added 18,000 thousand employees to its worldwide workforce last year, a 6.1 percent increase that comes as the company is trying to cut costs to shore up ...
Last March, executives at General Electric Co's (GE.N) power-plant business gave Wall Street a surprisingly bullish forecast for the year. Despite flat demand for new natural gas power plants, they said, GE Power's revenue and profit would rise. Showing data from financial firm Lazard and other sources, their presentation said natural gas, coal and even some nuclear power plants were the lowest-cost producers of electricity on the planet, cheaper than wind or solar.
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018. It expects to begin a tradipitant Phase 3 study in the first half of 2018 for atopic dermatitis and publish results from the tradipitant clinical study for the treatment of gastroparesis by the end of fiscal 2018.
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Vanda Pharmaceuticals (VNDA) is a biopharmaceutical company with a focus on developing and commercializing innovative therapies. Vanda Pharmaceuticals has adopted a five-pronged business strategy with a goal of becoming a leading global biopharmaceutical company.